openPR Logo
Press release

Endometriosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Enteris BioPharma, Spago Nanomedical, Iqvia Pty, Nanjing Chia-tai Tianqing Pharma, Myovant Sciences GmbH, Hope Medicine (Nanjing

05-09-2024 09:05 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Endometriosis Market is Predicted to Exhibit Remarkable Growth

DelveInsight's "Endometriosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Endometriosis, historical and forecasted epidemiology as well as the Endometriosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Endometriosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometriosis Market Forecast
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Endometriosis Market Report:
• The Endometriosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In November 2023, Gedeon Richter and Sumitomo Pharma jointly revealed that the European Commission had approved a Type II Variation application for RYEQO (consisting of relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg). This approval pertains to the symptomatic treatment of endometriosis in women who have undergone previous medical or surgical interventions for their condition.
• According to information from the World Health Organization (2023), approximately 10% of reproductive-age women and girls worldwide, totaling around 190 million individuals, are impacted by endometriosis.
• In 2023, the estimated number of diagnosed prevalent cases of endometriosis in the US stood at approximately 4,800,000 cases, with a potential increase anticipated by 2034.
• In 2023, it was noted that the largest population of individuals affected by endometriosis in the US fell within the 18-29 age bracket, with approximately 5,000,000 cases.
• In 2023, the diagnosed prevalent cases of endometriosis categorized by pain severity in the US were approximately 1,200,000 for mild, 1,900,000 for moderate, and 1,600,000 for severe. These figures are projected to increase during our forecast period from 2024 to 2034.
• Key Endometriosis Companies: Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others
• Key Endometriosis Therapies: Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 µg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others
• As per the findings of Yoshino et al. (2022), around 2.6 million women in Japan are impacted by endometriosis.
• The Endometriosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometriosis pipeline products will significantly revolutionize the Endometriosis market dynamics.

Endometriosis Overview
Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus. This tissue behaves like uterine lining, thickening and bleeding during the menstrual cycle. However, as it's displaced, it becomes trapped, leading to pain, inflammation, and sometimes fertility issues.

Get a Free sample for the Endometriosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Endometriosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endometriosis Epidemiology Segmentation:
The Endometriosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Endometriosis
• Prevalent Cases of Endometriosis by severity
• Gender-specific Prevalence of Endometriosis
• Diagnosed Cases of Episodic and Chronic Endometriosis

Download the report to understand which factors are driving Endometriosis epidemiology trends @ Endometriosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Endometriosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometriosis market or expected to get launched during the study period. The analysis covers Endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Endometriosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Endometriosis Therapies and Key Companies
• Leuprolide Oral Tablet: Enteris BioPharma Inc.
• SN132D: Spago Nanomedical AB
• OG-6219: Iqvia Pty Ltd
• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
• Relugolix: Myovant Sciences GmbH
• HMI-115: Hope Medicine (Nanjing) Co., Ltd
• Quinagolide 1080 µg: Ferring Pharmaceuticals
• OBE2109: ObsEva
• SASHR7280: Jiangsu HengRui Medicine
• Estradiol/Norethindrone Acetate: AbbVie
• TAK-385: ASKA Pharmaceutical Co., Ltd.
• NBI-56418 (GnRH antagonist): Abbott
• KLH-2109: Kissei Pharmaceutical Co., Ltd.
• Dienogest (Visanne, BAY86-5258): Bayer
• ERB-041: Pfizer

Discover more about therapies set to grab major Endometriosis market share @ Endometriosis Treatment Landscape
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Endometriosis Market Strengths
• The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms
• At national and international levels, government and key market players actively invest in research and development and increase funds, further catering to market growth.

Endometriosis Market Opportunities
• Incumbents are paired with healthcare providers to raise awareness in the field of endometriosis at the physician and patient levels
• New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool

Scope of the Endometriosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Endometriosis Companies: Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others
• Key Endometriosis Therapies: Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 µg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Endometriosis Unmet Needs, KOL's views, Analyst's views, Endometriosis Market Access and Reimbursement

To know more about Endometriosis companies working in the treatment market, visit @ Endometriosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Endometriosis Market Report Introduction
2. Executive Summary for Endometriosis
3. SWOT analysis of Endometriosis
4. Endometriosis Patient Share (%) Overview at a Glance
5. Endometriosis Market Overview at a Glance
6. Endometriosis Disease Background and Overview
7. Endometriosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Endometriosis
9. Endometriosis Current Treatment and Medical Practices
10. Endometriosis Unmet Needs
11. Endometriosis Emerging Therapies
12. Endometriosis Market Outlook
13. Country-Wise Endometriosis Market Analysis (2020-2034)
14. Endometriosis Market Access and Reimbursement of Therapies
15. Endometriosis Market Drivers
16. Endometriosis Market Barriers
17. Endometriosis Appendix
18. Endometriosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Endometriosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Enteris BioPharma, Spago Nanomedical, Iqvia Pty, Nanjing Chia-tai Tianqing Pharma, Myovant Sciences GmbH, Hope Medicine (Nanjing here

News-ID: 3491486 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Endometriosis

Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern. Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size? The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups. The
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five
Endometriosis Market Size, Share, Insight, Treatment 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Endometriosis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $2.01 billion In 2028 At A
Endometriosis Market Trends, Size, Forecast - 2018-2023
Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases it may occur in other parts of the body. The endometriosis leads to various physical symptoms such as severe menstrual cramps, nausea and vomiting, fatigue, diarrhea, constipation, long-term pelvic pain, and